Gosline, Sara J. C.
Tognon, Cristina
Nestor, Michael
Joshi, Sunil
Modak, Rucha
Damnernsawad, Alisa
Posso, Camilo
Moon, Jamie
Hansen, Joshua R.
Hutchinson-Bunch, Chelsea
Pino, James C.
Gritsenko, Marina A.
Weitz, Karl K.
Traer, Elie
Tyner, Jeffrey
Druker, Brian
Agarwal, Anupriya
Piehowski, Paul
McDermott, Jason E.
Rodland, Karin
Funding for this research was provided by:
National Cancer Institute (U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116, U01CA214116)
National Cancer Institute, United States (U24CA210955, R01CA229875-03, U24CA210955, U54CA224019-03, U54CA224019-03, R01CA229875-03, U24CA210955)
American Cancer Society (RSG-17-187-01-LIB, RSG-17-187-01-LIB)
Article History
Received: 20 January 2022
Accepted: 22 June 2022
First Online: 27 July 2022
Declarations
:
: All patients gave informed consent to participate in the Beat AML study, which had the approval and guidance of the Institutional Review Boards (IRB) from participating institutions. All samples used in this manuscript were collected at Oregon Health & Science University with a broad ‘research use’ clause.
: All authors consent for publication.
: All authors declare no competing interests.